• Explore /
  • Poster
  • / CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.

CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.

Abstract Poster

Authors

Michael Staehler

Michael D. Staehler

University Hospital Munich-Grosshadern, Ludwig Maximilian University, Munich, Germany

Michael D. Staehler , Paul Hamberg , Pierre Bigot , Cristina Suárez , Philippe Barthelemy , Jean-Christophe Eymard , Mathieu Laramas , Naila Taguieva Pioger , Marine Gross-Goupil , Michael Rink , Cristina Masini , Rocco De Vivo , Pablo Gajate , Ashraf Azzabi , Giuseppe Procopio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03419572; EUPAS19464

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS770)

Abstract #

TPS770

Poster Bd #

L4

Abstract Disclosures

Similar Posters

First Author: Antoine Thiery-Vuillemin

First Author: Michael D. Staehler

First Author: Frede Donskov

First Author: Mototsugu Oya